Atherosclerosis is not, at its root, a cholesterol problem. It's a problem of vascular biology - of how lipoprotein particles, the endothelial surface they cross, and the inflammatory response to them interact over a lifetime. Three categories organize everything that follows: the lipoprotein profile that supplies the raw material, the endothelial function that decides whether that material gets in, and the inflammatory response that decides what happens once it does. All three can be influenced deliberately, and each has a point where self-directed support ends and your cardiologist begins.
Before you begin
Is this for you?
This guide is for
- Adults who want to change their cardiovascular trajectory in the decades before an event is ever on the table - not simply react to a bad lipid panel
- People who have seen borderline or rising markers - apolipoprotein B (ApoB), lipoprotein(a) [Lp(a)], triglycerides, high-sensitivity C-reactive protein (hs-CRP) - and want to understand what they mean before reaching for, or alongside, medication
- Anyone with a family history of early heart disease who wants to know which dials are worth tracking and which levers move them
- People who want to understand the difference between lowering a cholesterol number and changing the vascular biology underneath it - and why the two aren't the same
This guide is not for
- Anyone having cardiac symptoms right now - chest pain or pressure, pain into the arm or jaw, sudden breathlessness. That is not a self-care conversation. Call emergency services. Nothing in this guide is for an acute event.
- People with established disease or very high-risk markers - a prior heart attack or stroke, a coronary calcium score above 300, unstable angina, or familial hypercholesterolemia. The protocol here is adjunctive; your management belongs with a cardiologist.
- Anyone hoping a supplement stack will let them avoid the upstream variables - blood pressure, sleep, glucose, visceral fat, stress. That is where the leverage is; the stack supports that work, it doesn't replace it.
The mechanism
How atherosclerosis progresses
The disease is slow, silent, and remarkably consistent in its choreography. An apoB-bearing particle crosses a compromised endothelial surface and lodges in the arterial wall. It's oxidized. The immune system answers - monocytes arrive, become macrophages, engulf the oxidized lipid, and turn into foam cells. Those foam cells accumulate into a fatty streak, then a fibrous plaque. Most plaques stay stable for decades. The dangerous ones aren't the largest but the most inflamed: a thin-capped, lipid-rich lesion that ruptures, triggers a clot, and produces the event. The pathology that shows up as a heart attack at sixty begins in the arterial wall in your thirties.
The lipoprotein profile - particle count, not cholesterol content
LDL-C measures the cholesterol carried inside low-density lipoprotein (LDL) particles; it says nothing about how many particles there are. Two people with identical LDL-C can carry very different particle burdens - and it's the particle count, not the cholesterol cargo, that drives risk. Every atherogenic particle carries exactly one apoB protein, which is what makes apoB the cleanest single measure of how many wall-penetrating particles are in circulation.
Lp(a) is a genetically determined, largely diet-independent particle that adds an inherited tier of risk on top of everything else - and roughly one in five people carry enough of it to matter. It's checked once in a lifetime, and it reframes how aggressive the rest of the plan should be.
Endothelial function - the surface where plaque begins
Before a particle can lodge in the wall, it has to get past the endothelium - and specifically past the glycocalyx, the gel-like protective layer that lines every blood vessel. A healthy glycocalyx is a non-stick surface; particles pass by. A degraded one is a surface particles can breach and embed in. This is the interface where the familiar risk factors do their damage: high blood pressure, high blood sugar, oxidative stress, and elevated homocysteine all converge on the glycocalyx, thinning it and making the wall permeable.
The surface comes first. You can have a clean lipid panel and still progress if the surface is compromised - and you can carry a less-than-perfect panel and stay stable if the surface holds. Protecting and rebuilding that surface intervenes at the point where entry is decided.
Inflammation - failed resolution, not excess activation
The inflammatory response to a trapped, oxidized particle is supposed to be self-limiting: activate, clear the debris, then actively switch off. That off-switch is its own biological program - resolution, driven by specialized pro-resolving mediators (SPMs) made from omega-3 fatty acids. Atherosclerosis is better understood as a failure of resolution than as an excess of activation. The fire isn't the whole problem; the inability to put it out is.
The distinction decides which tool you reach for. Blunting activation and restoring resolution are different jobs requiring different inputs, and a plan that collapses them under one word, "anti-inflammatory," will under-serve both.
Each category runs on its own mechanism and takes its own tools:
Reducing the number of atherogenic particles and managing the inherited Lp(a) burden - fewer particles arriving at the wall, and better handling of the clotting risk Lp(a) carries. The raw-material supply side of the equation.
Rebuilding the glycocalyx, defending it against the agents that degrade it, and supporting healthy nitric-oxide signaling and vasodilation. The surface that decides whether particles ever get in.
Restoring the resolution program that switches inflammation off, and calming the activation side where it runs hot. Two distinct jobs: supplying the pro-resolving mediators and easing the activation cascade.
Upstream of the wall
The metabolic accelerants
The three categories describe the machinery; for many people a single upstream driver feeds two of them at once - metabolic dysfunction. Carrying excess weight, running high blood sugar, and running high insulin accelerate this same disease, through the glycocalyx and the inflammatory response. When they're present, they're usually the dominant contributors - and the most worth addressing first.
Visceral fat is an inflammatory organ
Visceral adipose tissue, the fat stored around the organs, behaves like an endocrine gland: as the cells enlarge they recruit immune cells and secrete a steady output of inflammatory signals - interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), leptin - while the protective signal, adiponectin, falls. That raises the body's resting inflammatory tone, which is precisely the activation the resolution program is already straining to switch off. This is how excess weight feeds the inflammatory response: as a source of the inflammation that keeps the plaque hot. It's also why the number that matters is visceral fat mass, not body weight - the fat carried around the waist is the metabolically active kind.
High glucose erodes the surface
Sustained high blood sugar is one of the agents that degrades the glycocalyx directly. Glucose shears the protective mesh, and over time it drives the formation of advanced glycation end-products that stiffen the arterial wall and quench the nitric oxide the endothelium needs to stay relaxed and non-stick. The surface you're working to protect erodes fastest in a high-glucose environment. This is hyperglycemia eroding the endothelial surface, at the exact interface where particles decide whether they get in.
High insulin raises vascular resistance
In a healthy vessel, insulin is a vasodilator: it tells the endothelium to make nitric oxide and relax, widening the vessel as it goes. In insulin resistance that instruction is selectively blunted - the relaxing signal weakens while the constricting signals carry on - so vascular tone climbs, blood pressure rises, and that elevated pressure becomes its own degrading force on the same surface. Insulin is also a growth signal, not only a tone signal: chronically high levels act on the smooth muscle of the arterial wall directly, driving the hypertrophy of the tunica media and intima that thickens, narrows, and stiffens the vessel - a structural rise in resistance, not just a functional one. Systemic vascular resistance, the term for how hard the vessels squeeze against the blood moving through them, is the through-line: high insulin raises it functionally and structurally at once, and a higher-pressure system wears the glycocalyx down. Hyperinsulinemia attacks Category #2 from a second direction.
The same insulin-resistant state shifts the particle profile toward small, dense LDL and triglyceride-rich very-low-density lipoprotein (VLDL) remnants - which is why the triglyceride-to-high-density lipoprotein (HDL) ratio reads as a metabolic surrogate. The metabolic picture and the particle picture move together.
What we watch
The dials worth tracking
Risk here is multi-dimensional, so no single number tells the story. These are the markers that, read together, describe the particle burden, the state of the surface, and the inflammatory tone - the three categories made measurable.
Coronary artery calcium (CAC) score · resting blood pressure · CT coronary angiogram · endothelial function testing (EndoPAT) · visceral fat mass.
This isn't an exhaustive list.
No results to work from yet? FullMetrics / GeneMetrics runs panels deep enough to be worth reading.
Before the protocol
Invulnerability, catastrophizing, and the stress that feeds both
Two postures tend to bracket this subject, and both are obstacles. The first is invulnerability - the quiet conviction that heart disease happens to other people, that a good week at the gym settles the question, that the silence of the disease means its absence. The second is its mirror: a catastrophizing dread that reads every chest twinge as the beginning of the end. The first posture skips the decades of quiet work the disease responds to. The second floods the body with the very stress that accelerates it.
Stress is part of the vascular mechanism. Sustained cortisol raises blood pressure and blood sugar, and a chronically activated autonomic state keeps the vessel wall under exactly the kind of pressure and oxidative load that thins the glycocalyx. The anxiety about the arteries becomes an input to the arteries, which is a reason to resource the nervous system as deliberately as you resource the lipid panel.
The useful middle treats cardiovascular risk as a trajectory measured in decades, mostly silent and mostly modifiable, and works it steadily in the years when the work compounds.
How to supplement
A three-month nutraceutical trial
Give the trial a defined window, retest, and judge it by the numbers rather than by feel - atherosclerosis produces no symptoms to track, so the markers are the only feedback you get. Most of these products can run continuously; the point of a three-month frame is to create a clear before-and-after you can act on.
A polyphenol extract from bergamot fruit. Its main compounds, brutieridin and melitidin, are built like the part of a statin that fits the cholesterol-making enzyme, and small trials have found modest drops in LDL cholesterol and triglycerides. Whether it slows that enzyme in people hasn't been shown, and the effect is much smaller than a statin's, so it's a modest option for an early or moderate particle burden. It isn't a substitute for a statin your prescriber has recommended or stopped.
A fibrinolytic enzyme blend aimed at the clotting half of the Lp(a) problem. Apolipoprotein(a), the apo(a) tail on the particle, carries looped protein segments (kringles) shaped like plasminogen's, which is why Lp(a) is thought to get in the way of clot breakdown; the proteases in this blend (Nattozimes and Serrazimes, from Aspergillus, matched to nattokinase and serrapeptase by their activity in laboratory tests) are taken to break down fibrin - the clot-dissolving side of the ledger - which is why it earns a place when Lp(a) runs high. In my clinical experience, elevated Lp(a) has come down with consistent use. It's best taken away from food. If you take a blood thinner or daily aspirin, or have a bleeding disorder, check with your prescriber first.
Arterosil HP is the rebuilding piece; TMG, 5-MTHF Plus B12, NAC, and aged garlic lower what degrades the surface; NOVA Complete feeds its signaling.
The one item in the stack that actively rebuilds the endothelial surface. Its rhamnan-sulfate complex supplies the building blocks the body uses to regenerate the glycocalyx - structural repair of the protective surface that decides whether particles ever breach the wall.
One of two parallel routes for clearing homocysteine - an amino acid that, left elevated, is among the agents that degrade the glycocalyx. TMG drives the betaine-homocysteine methyltransferase (BHMT) pathway, donating a methyl group to convert homocysteine back into methionine. It runs in parallel with the folate route that 5-MTHF Plus B12 supports; the two are independent methyl-donor pathways toward the same end, which is why both can earn a place when homocysteine is high.
The second homocysteine route, running through the folate cycle rather than the BHMT pathway. Active folate (5-MTHF) with B12 drives the methionine-synthase remethylation of homocysteine - the parallel methyl-donor pathway to TMG, not a substitute for it. The active forms matter for the substantial share of people whose genetics handle synthetic folate poorly.
Sulfation and antioxidant defense for the surface. NAC is the rate-limiting precursor the body uses to make glutathione, its principal endogenous antioxidant - which defends the endothelium against the oxidative stress that thins the glycocalyx.
Aged garlic's S-allylcysteine supports healthy nitric-oxide signaling and helps hold blood pressure in a favorable range - easing one of the mechanical and oxidative forces that wear on the glycocalyx.
L-citrulline and beetroot-derived nitrates feed the nitric-oxide pathway directly, supporting the vasodilation and healthy blood flow a well-functioning endothelium is meant to produce.
Specialized pro-resolving mediators - the molecules that operate the resolution off-switch. Rather than blunting inflammation, these supply the active signal that tells an inflammatory response to stand down and clear. Because atherosclerosis is more a failure of resolution than an excess of activation, this targets the half of the problem anti-inflammatories leave untouched.
High-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the triglyceride form for better absorption - the raw substrate the body builds pro-resolving mediators from. SPMs supply the finished signal; this keeps the supply line for making your own well stocked, and at therapeutic dosing moves the triglyceride and Omega-3 Index numbers in the right direction. If you've had atrial fibrillation, talk with your prescriber before you start: at these doses, fish oil raises the chance of atrial fibrillation.
Vitamin D3 with K1 and K2 (as MK-4). Vitamin D is an immunomodulator that helps keep the inflammatory tone measured rather than reactive; K2 directs calcium toward bone and away from the arterial wall - the relevant concern as plaques calcify. It's worth testing and titrating vitamin D rather than guessing; aim for a 25-hydroxyvitamin D (25-OH-D) in the sufficient range. If you take warfarin, get your INR checked within two weeks of starting or stopping D-Evail Supreme, because of the vitamin K it contains.
PEA with Meriva curcumin works the activation side, where SPM Supreme works resolution. Palmitoylethanolamide (PEA) and a bioavailable curcumin calm the nuclear factor kappa B (NF-κB) and cyclooxygenase-2 (COX-2) signaling that drives the inflammatory response, with curcumin also engaging peroxisome proliferator-activated receptor alpha (PPAR-α). Where SPMs switch inflammation off, this turns down the volume on what switches it on - two different jobs, which is why both can sit in the same stack. If you take warfarin, get your INR checked within two weeks of starting or stopping the curcumin, which raised INR in case reports.
After three months, retest the markers that move on this timescale - ApoB, hs-CRP, homocysteine, and the triglyceride-to-HDL ratio - and decide what to keep. Lp(a) is genetic and won't shift; the others will tell you whether the plan is working. Bring the before-and-after to whoever manages your cardiovascular care.
Upstream of every supplement
The levers that aren't in a bottle
No stack outperforms the foundation it sits on. These move the same biology the supplements target - and they move it harder:
- Blood pressure - measure it at home and keep it in range. Pressure is a mechanical force on the glycocalyx; sustained elevation wears the surface down faster than any supplement rebuilds it.
- Zone-2 cardiovascular training - steady aerobic work most days, at a pace where you can still hold a conversation, builds mitochondrial and endothelial capacity and supports nitric-oxide signaling. Few single inputs touch this much of the vascular picture at once.
- Sleep architecture - deep, sufficient sleep is when blood pressure dips and the vasculature recovers. Chronic short sleep raises cardiovascular risk on its own, independent of everything else on this page.
- Metabolic foundation - glucose, insulin, and visceral fat drive both particle number and surface damage. Reducing refined carbohydrate is the fastest lever on the triglyceride-to-HDL ratio.
Do these and the stack compounds. Skip them and you're asking twelve supplements to outrun a headwind they were never meant to fight alone.
Where prevention hands off to clinical care
What belongs to your physician
The highest-value move in this guide is matching the intensity of your response to your risk, and that calibration is a clinical judgment. Borderline markers in an otherwise healthy adult are a different situation from a strong family history stacked on top of a high Lp(a), and they call for different aggressiveness.
The following are physician decisions, full stop:
- A strong family history or a high Lp(a) - early heart disease in first-degree relatives, or an Lp(a) in the high range, changes how aggressive your entire plan should be. That calibration belongs with a provider.
- Established disease or very high-risk numbers - a prior heart attack or stroke, a coronary calcium score above 300, unstable angina, familial hypercholesterolemia, or an ApoB well above range. Adjunctive support is not management; this is a cardiologist's territory.
- Ordering and interpreting a CAC scan or CT angiogram - imaging decisions, and what to do with the results, belong with your provider.
- Prescription lipid-lowering - statins, ezetimibe, and PCSK9 inhibitors are physician decisions. The nutraceutical work here sits alongside them, not in place of them; for many people, medication is the right tool.
- A blood thinner, daily aspirin or a bleeding disorder - check with your prescriber before you start Natto-Serrazime, and if you take warfarin, get your INR checked after starting or stopping D-Evail Supreme or the Meriva curcumin.
The bottom line
Trajectory, not destiny
Atherosclerosis is a decades-long process, mostly silent and mostly modifiable. The leverage isn't in the year you have the scare - it's in the twenty years before it, when small, consistent inputs compound into a different arterial wall. Match the tool to the category: particle number on the supply side, the glycocalyx and its defenses at the surface, resolution and activation on the inflammatory side.
Then know your two thresholds. The first is the line where ordinary prevention gives way to clinical care - established disease, very high-risk markers, a family history that changes the math. The second is not negotiable: chest pain, pressure, or sudden breathlessness is an emergency, not a supplement decision. The people whose arteries age slowest started early, retested on schedule, and knew which threshold they were standing on.
Protect the glycocalyx first. Resolve the inflammation. Then address the particle number. In that order, for most people, you're working the mechanism from the surface inward rather than only at the number.
This guide is educational and isn't a substitute for individualized care from a licensed healthcare provider. Nothing here is a diagnosis or a prescription. Talk to your physician before starting, stopping, or changing any supplement, medication, or treatment - especially if you've established cardiovascular disease, take an anticoagulant or other prescription medication, or are pregnant or managing a chronic condition. Merlin may earn a commission on products purchased through the Fullscript plans linked here.
Read this against your own results. Bring what you have - any lab, any year, any provider. Your first month reads your results together, every result against every other, and starts you where it matters most.
Start your first month - $35If you don't feel the value of Merlin after paying for your first month, tell us and we'll refund you in full. Monthly Core, once per person, by email within 30 days. The terms →
No results yet? Bring labs from anywhere, order our $180 baseline panel inside Merlin, or start with the questions, free.
Work with a practitioner. Some pictures want a second set of eyes and a plan you did not have to build yourself.
Start a conversation~ Your health data is never used to train AI. ~